Role of phospholipase D in tumorigenesis

磷脂酶 D 在肿瘤发生中的作用

基本信息

  • 批准号:
    7257202
  • 负责人:
  • 金额:
    $ 19.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1989
  • 资助国家:
    美国
  • 起止时间:
    1989-08-25 至 2009-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Elevated phospholipase D (PLD) activity has been reported in several types of human cancer including breast, kidney, colon and gastric cancer. Recent work has revealed that elevated PLD activity in human breast cancer cells can suppress apoptosis and promote cell migration - two critical steps in progression to a malignant cancer. The survival and migration signals generated by PLD are mediated - at least in part - by mTOR (the mammalian target of rapamycin), which has been widely implicated in cancer survival signals. While it is clear that PLD is capable of contributing to tumorigenesis and that PLD activity is elevated in a large number of human cancers, it is not known how and in what context elevated PLD activity contributes to the transformation of human cells or tumorigenesis in an animal. There is also much to be learned about the signaling pathways that activate PLD in human cancer cells. The Central Hypothesis of the proposal is that: PLD generates signals that suppress apoptosis and enhance cell migration in human cancer cells. Specifically, we propose to: 1) Characterize signals regulating PLD activity in human cancer cell lines and to evaluate targeting these signals pharmacologically both in vitro and in vivo; 2) Investigate a role for PLD survival signals in cell migration and metastasis; and 3) Evaluate the ability of PLD to cooperate with oncogenes to transform human cells in culture and to stimulate cell migration. The ability of PLD to both suppress apoptosis and enhance cell migration makes PLD an ideal target for the development of therapeutic strategies. As the era of molecular medicine and pathology evolves and individual tumors are examined at the molecular level, elevated PLD activity could be easily determined and the signals generated by PLD activity could then be targeted specifically. The studies proposed here will provide a conceptual framework for rational targeting of the apparent large number of human cancers with elevated PLD activity.
描述(由申请人提供):在几种类型的人类癌症(包括乳腺癌、肾癌、结肠癌和胃癌)中报告了磷脂酶D(PLD)活性升高。最近的研究表明,人乳腺癌细胞中PLD活性的升高可以抑制细胞凋亡并促进细胞迁移-这是恶性肿瘤进展的两个关键步骤。PLD产生的存活和迁移信号至少部分地由mTOR(雷帕霉素的哺乳动物靶标)介导,mTOR已广泛涉及癌症存活信号。虽然PLD能够促进肿瘤发生并且PLD活性在大量人类癌症中升高是清楚的,但是尚不知道升高的PLD活性如何以及在何种情况下促进人类细胞的转化或动物中的肿瘤发生。关于激活人类癌细胞中PLD的信号通路,还有很多东西需要了解。该提案的中心假设是:PLD产生抑制人类癌细胞凋亡和增强细胞迁移的信号。具体而言,我们建议:1)表征调节人癌细胞系中PLD活性的信号,并评估体外和体内靶向这些信号的能力; 2)研究PLD存活信号在细胞迁移和转移中的作用;和3)评估PLD与癌基因合作以转化培养物中的人细胞并刺激细胞迁移的能力。PLD抑制细胞凋亡和增强细胞迁移的能力使PLD成为开发治疗策略的理想靶点。随着分子医学和病理学时代的发展以及在分子水平上检查个体肿瘤,可以容易地确定升高的PLD活性,然后可以特异性地靶向PLD活性产生的信号。这里提出的研究将提供一个概念性的框架,合理的目标明显大量的人类癌症与PLD活性升高。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID A FOSTER其他文献

DAVID A FOSTER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID A FOSTER', 18)}}的其他基金

Dysregulated Metabolic Cell Cycle Checkpoints in Human Cancer
人类癌症中代谢细胞周期检查点失调
  • 批准号:
    8910668
  • 财政年份:
    2014
  • 资助金额:
    $ 19.19万
  • 项目类别:
Dysregulated Metabolic Cell Cycle Checkpoints in Human Cancer
人类癌症中代谢细胞周期检查点失调
  • 批准号:
    9326198
  • 财政年份:
    2014
  • 资助金额:
    $ 19.19万
  • 项目类别:
Dysregulated Metabolic Cell Cycle Checkpoints in Human Cancer
人类癌症中代谢细胞周期检查点失调
  • 批准号:
    8773710
  • 财政年份:
    2014
  • 资助金额:
    $ 19.19万
  • 项目类别:
Tumor Suppression by Protein Kinase C-delta
蛋白激酶 C-delta 抑制肿瘤
  • 批准号:
    6772199
  • 财政年份:
    2004
  • 资助金额:
    $ 19.19万
  • 项目类别:
PHOSPHOLIPIDN METABOLISM ACTIVATED BY V-SRC
V-SRC 激活磷脂代谢
  • 批准号:
    6240183
  • 财政年份:
    1997
  • 资助金额:
    $ 19.19万
  • 项目类别:
BASIS FOR TRANSFORMATION BY FUJINAMI SARCOMA VIRUS
富士肉瘤病毒转化的基础
  • 批准号:
    3458698
  • 财政年份:
    1989
  • 资助金额:
    $ 19.19万
  • 项目类别:
BASIS FOR TRANSFORMATION BY FUJINAMI SARCOMA VIRUS
富士肉瘤病毒转化的基础
  • 批准号:
    3458702
  • 财政年份:
    1989
  • 资助金额:
    $ 19.19万
  • 项目类别:
Role of phospholipase D in tumorigenesis
磷脂酶 D 在肿瘤发生中的作用
  • 批准号:
    7144110
  • 财政年份:
    1989
  • 资助金额:
    $ 19.19万
  • 项目类别:
Phospholipase D-mTOR Survival Signals in Tumorigenesis
肿瘤发生中的磷脂酶 D-mTOR 存活信号
  • 批准号:
    8396559
  • 财政年份:
    1989
  • 资助金额:
    $ 19.19万
  • 项目类别:
MITOGENIC SIGNALING THROUGH RAL A AND PHOSPHOLIPASE D
通过 RAL A 和磷脂酶 D 的有丝分裂信号传导
  • 批准号:
    7050475
  • 财政年份:
    1989
  • 资助金额:
    $ 19.19万
  • 项目类别:

相似海外基金

Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
  • 批准号:
    8077875
  • 财政年份:
    2010
  • 资助金额:
    $ 19.19万
  • 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
  • 批准号:
    7866149
  • 财政年份:
    2010
  • 资助金额:
    $ 19.19万
  • 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
  • 批准号:
    8589822
  • 财政年份:
    2010
  • 资助金额:
    $ 19.19万
  • 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
  • 批准号:
    8305149
  • 财政年份:
    2010
  • 资助金额:
    $ 19.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了